17 completed, 4 unknown, 2 recruiting, 1 active not recruiting. 25 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 25 | Completed 17, Unknown 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Postmenopausal Osteoporosis: new trials by email Literature Review of Postmenopausal Osteoporosis trials Research Report on Postmenopausal Osteoporosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romosozumab and Denosumab Combination Therapy for Osteoporosis Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2027-01-01 | 2026-11-03 |
| The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation Ibandronate IV, Zoledronic acid IV - Postmenopausal Osteoporosis, Postmenopausal Osteopenia | Phase 4 | Recruiting | National Taiwan University Hospital | 52 | 2026-08-20 | 2026-08-25 |
| StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis a second infusion of ZOL when crosslaps levels reach 300 pg/mL, a rescue second infusion at month-12 (standard traitment) - Postmenopausal Osteoporosis | Phase 4 | Recruiting | University Hospital, Toulouse | 200 | 2025-10-02 | 2025-12-31 |
| A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. Romosozumab - Postmenopausal Osteoporosis | Phase 4 | Completed | Amgen | 100 | 2023-10-30 | 2026-10-21 |
| Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis Eldecalcitol capsules, Calcitriol capsules - Low Bone Mineral Density, Postmenopausal Osteoporosis | Phase 4 | Unknown | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 300 | 2023-09-27 | 2024-05-16 |
| Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination - Postmenopausal Osteoporosis | Phase 4 | Completed | Dong-A ST Co., Ltd. | 149 | 2023-01-03 | 2025-08-24 |
| Efficacy and Safety of Minodronate in Patients With Low Back Pain Minodronate, Alendronate - Postmenopausal Osteoporosis | Phase 4 | Unknown | Peking University Third Hospital | 72 | 2023-01-01 | 2022-12-09 |
| Anabolic Therapy in Postmenopausal Osteoporosis Romosozumab, Denosumab - Postmenopausal Osteoporosis | Phase 4 | Active not recruiting | Massachusetts General Hospital | 50 | 2022-03-24 | 2026-04-15 |
| Pravastatin Reduces Acute Phase Response of Zoledronic Acid Pravastatin Sodium 80 MG, Placebo - Postmenopausal Osteoporosis | Phase 4 | Unknown | Peking University Third Hospital | 110 | 2021-11-01 | 2021-06-23 |
| Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid Zoledronic Acid Injection, Placebo - Postmenopausal Osteoporosis | Phase 4 | Unknown | Peking University Third Hospital | 64 | 2021-10-01 | 2021-06-23 |
| Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Teriparatide, Denosumab - Postmenopausal Osteoporosis | Phase 4 | Completed | Massachusetts General Hospital | 37 | 2019-09-02 | 2023-08-02 |
| MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis Prolia, 60 Mg/mL Subcutaneous Solution, Teriparatide - Postmenopausal Osteoporosis, Diabetes Type 2 | Phase 4 | Completed | Medical University of Vienna | 26 | 2017-03-01 | 2023-01-26 |
| Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation Denosumab, Zoledronic acid - Postmenopausal Osteoporosis | Phase 4 | Completed | 424 General Military Hospital | 57 | 2015-07-01 | 2019-03-11 |
| Denosumab and Teriparatide Study (DATA-HD and DATA-EX) denosumab, teriparatide, Zoledronic acid - Postmenopausal Osteoporosis | Phase 4 | Completed | Massachusetts General Hospital | 76 | 2014-08-01 | 2021-02-09 |
| Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet - Postmenopausal Osteoporosis | Phase 4 | Completed | Massachusetts General Hospital | 27 | 2013-01-01 | 2017-03-27 |
| VERtebral Fracture Treatment Comparisons in Osteoporotic Women Teriparatide, Risedronate, Placebo - Postmenopausal Osteoporosis | Phase 4 | Completed | Eli Lilly and Company | 1366 | 2012-10-01 | 2019-09-23 |
| Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Raloxifene, Strontium ranelate - Postmenopausal Osteoporosis, Compliance | Phase 4 | Completed | University of Valencia | 80 | 2009-09-01 | 2012-09-03 |
| A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Placebo, ibandronate - Postmenopausal Osteoporosis | Phase 4 | Completed | Hoffmann-La Roche | 140 | 2006-05-01 | 2016-05-12 |
| A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Ibandronate - Postmenopausal Osteoporosis | Phase 4 | Completed | Hoffmann-La Roche | 716 | 2006-04-01 | 2016-10-24 |
| BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis ibandronate [Bonviva/Boniva] - Postmenopausal Osteoporosis | Phase 4 | Completed | Hoffmann-La Roche | 585 | 2006-03-01 | 2016-11-02 |
Showing 20 of 25. Sign in to see all of them.
Osteoporosis, Postmenopausal (25) · Osteoporosis (5) · Bone Diseases, Metabolic (3) · Acute-Phase Reaction (1) · Diabetes Mellitus, Type 2 (1) · Low Back Pain (1) · Patient Compliance (1) · Spinal Fractures (1)
Bone Diseases (25) · Metabolic Diseases (25) · Musculoskeletal Diseases (25) · Nutritional and Metabolic Diseases (25) · Bone Diseases, Metabolic (22) · Osteoporosis (20) · Pathological Conditions, Signs and Symptoms (2) · Back Injuries (1) · Back Pain (1) · Behavior (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Fractures, Bone (1) · Glucose Metabolism Disorders (1) · Health Behavior (1)
Denosumab (7) · Teriparatide (7) · Ibandronic Acid (6) · Alendronate (3) · Zoledronic Acid (3) · romosozumab (3) · Raloxifene Hydrochloride (2) · Risedronic Acid (2) · strontium ranelate (2) · Calcitriol (1) · Calcium (1) · Injections, Subcutaneous (1) · Pravastatin (1) · Vitamin D (1) · YM 529 (1)
Hoffmann-La Roche (6) · Massachusetts General Hospital (5) · Eli Lilly and Company (3) · Peking University Third Hospital (3) · 424 General Military Hospital (1) · Amgen (1) · Dong-A ST Co., Ltd. (1) · Medical University of Vienna (1) · National Taiwan University Hospital (1) · Shanghai Jiao Tong University Affiliated Sixth People's Hospital (1) · University Hospital, Toulouse (1) · University of Valencia (1)
United States (9) · Greece (4) · Austria (3) · Spain (3) · Belgium (2) · China (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Poland (2) · Argentina (1) · Brazil (1) · Canada (1) · Finland (1)
Benjamin Leder, MD (3) · Chunli Song, M.D.; Ph. D. (2) · Antonio Cano, MD (1) · Athanasios D Anastasilakis, PhD (1) · Chunli Song, Pro. (1) · Polyzois Makras, PhD (1) · Zhenlin Zhang (1)
PMID 11138687, PMID 1421796, PMID 18539106, PMID 19584192, PMID 19671655, PMID 21289258, PMID 25933031, PMID 28240371, PMID 28546097, PMID 29105841, PMID 29129436, PMID 29329484, PMID 30659410, PMID 31433518, PMID 31447409, PMID 31665314, PMID 32157334, PMID 32474650, PMID 32707115, PMID 33386953, PMID 33813753, PMID 34009703, PMID 35478046, PMID 35831045, PMID 36088628, PMID 36602607, PMID 37798320, PMID 39135126, PMID 39527056, PMID 39933434, PMID 40057981, PMID 41621431, PMID 9425497
2005 (1), R01AR073191 (1)